Patient P-02611
Therapy response
Improving
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
21%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S17
- Day 108 AD-05 recommended — Adherence Support AD-05
- Day 109 Patient declined — Not now
- Day 128 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 128.
Primary contributors, last 14 days
- GI instability+7
- Treatment adherence-6
- Toxicity+3
What helped?
- Adherence Support AD-05Day 108Declined by patient
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable87 min
stable · -0.4 vs previous 14 d
Sleep duration
Wearable6.2 h
stable · +0.1 vs previous 14 d
Energy level
Daily log5.9/10
stable · -0.1 vs previous 14 d
Steps
Wearable9,665
stable · -140 vs previous 14 d
GI burden
Companion12.8/100
worsening · +3.4 vs previous 14 d
Adherence
Companion80.9 %
worsening · -3.9 vs previous 14 d
Sleep quality
Wearable47.9/100
improving · +2.6 vs previous 14 d
Glucose, CGM daily mean
CGM127 mg/dL
stable · +0.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 76 from the failing basin, 34 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.9 next day on high-intake days · n 21
Would not help
- BR-03 Behavioural Recommendationonly 20% improved among 10 similar
- Keep fibre lowGI +3.4 next day on high-intake days · n 11
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.9supporter · 95%
- Insoluble fibre+3.4detractor · 76%
- Ultra-processed food+2.3no signal · 45%
- Histamine load+2no signal · 52%
- Caffeine+1.6no signal · 36%
- Alcohol-1.1no signal · 30%
- Simple carbohydrates-0.6no signal · 17%
- Dietary fat load+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.3 · butyrate capacity 79/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 54 ms
- Sleep
- 6.6 h
- Steps
- 9,722
- Resting HR
- 59 bpm
Daily log: GI score 13, nutritional resilience 68, adherence 81.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02031 | 52% | S12 | AD-05 | improved | 47 |
| P-02285 | 43% | S14 | AD-05 | no change | 39 |
| P-02093 | 39% | S05 | AD-05 | no change | 40 |
| P-02522 | 43% | S01 | BR-03 | no change | 40 |
| P-02087 | 42% | S01 | BR-03 | no change | 40 |
| P-02638 | 39% | S01 | BR-03 | improved | 41 |
| P-02267 | 37% | S09 | BR-03 | no change | 45 |
| P-02439 | 36% | S08 | BR-03 | no change | 40 |
| P-02308 | 35% | S13 | BR-03 | no change | 27 |
| P-02325 | 33% | S19 | BR-03 | no change | 33 |
| P-02280 | 32% | S07 | BR-03 | no change | 50 |
| P-02331 | 30% | S14 | BR-03 | improved | 34 |